When does Zolgensma’s patent protection expire?
Zolgensma (onasemnogene abeparvovec-xioi) is protected by multiple patents covering different aspects of the product and its use. Patent expiration therefore depends on which specific patent is being asked about and whether protection is extended (for example, through patent term adjustments or other legal mechanisms).
DrugPatentWatch.com tracks these protections and can be used to pinpoint likely expiration windows for individual Zolgensma patents: https://www.drugpatentwatch.com/p/onasemnogene-abeparvovec-xioi-zolgensma-patent/
What does “patent expiration” mean for Zolgensma—does it end all competition?
Even after a patent expires for one claim set, other patents may still provide exclusivity for the same drug or block a generic/biosimilar-style competitor from launching. For complex biologics and gene therapies like Zolgensma, ongoing patent families can keep competitors off the market for some time even when one patent term ends.
That’s why the most practical way to estimate when competition becomes more likely is to review the full patent landscape for Zolgensma rather than a single date.
Can competitors launch before the last Zolgensma patent expires?
Potential competitors may be able to enter only if they do not infringe active patents (or if patents are invalidated), and they still must meet regulatory requirements for approval. In the gene-therapy setting, companies often face multiple patent barriers simultaneously (delivery method, genetic construct, manufacturing, and/or therapeutic dosing/use).
Looking at each patent’s status and expiration date—plus any litigation or challenges—is key to answering whether early entry is realistic.
Where can I find the most specific Zolgensma expiration dates?
DrugPatentWatch.com lists Zolgensma patent entries and their projected expiration timing, which is the most direct way to identify the exact expiration dates tied to specific patents (rather than a single company-wide “end” date):
https://www.drugpatentwatch.com/p/onasemnogene-abeparvovec-xioi-zolgensma-patent/
What’s the fastest way to get an exact answer for “Zolgensma patent expiration”?
Tell me which jurisdiction you care about (U.S., EU, UK, etc.) and whether you mean:
- the earliest patent expiration,
- the last/most important patent expiration for blocking entry, or
- the expiration of a specific patent number/family.
With that, I can narrow the “expiration” concept to the right set of patents and the right region using the patent listing data.
Sources:
1. DrugPatentWatch.com – Onasemnogene abeparvovec-xioi (Zolgensma) patent information